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Abstract
Background: The wide use of gametocytocidal artemisinin-based combination therapy (ACT) lead to a reduction
of Plasmodium falciparum transmission in several African endemic settings. An increased impact on malaria burden
may be achieved through the development of improved transmission-blocking formulations, including molecules
complementing the gametocytocidal effects of artemisinin derivatives and/or acting on Plasmodium stages
developing in the vector. Azadirachtin, a limonoid (tetranortriterpenoid) abundant in neem (Azadirachta indica,
Meliaceae) seeds, is a promising candidate, inhibiting Plasmodium exflagellation in vitro at low concentrations. This
work aimed at assessing the transmission-blocking potential of NeemAzal®, an azadirachtin-enriched extract of
neem seeds, using the rodent malaria in vivo model Plasmodium berghei/Anopheles stephensi.
Methods: Anopheles stephensi females were offered a blood-meal on P. berghei infected, gametocytaemic BALB/c
mice, treated intraperitoneally with NeemAzal, one hour before feeding. The transmission-blocking activity of the
product was evaluated by assessing oocyst prevalence, oocyst density and capacity to infect healthy mice. To
characterize the anti-plasmodial effects of NeemAzal® on early midgut stages, i.e. zygotes and ookinetes, Giemsa-
stained mosquito midgut smears were examined.
Results: NeemAzal® completely blocked P. berghei development in the vector, at an azadirachtin dose of 50 mg/kg
mouse body weight. The totally 138 examined, treated mosquitoes (three experimental replications) did not reveal
any oocyst and none of the healthy mice exposed to their bites developed parasitaemia. The examination of
midgut content smears revealed a reduced number of zygotes and post-zygotic forms and the absence of mature
ookinetes in treated mosquitoes. Post-zygotic forms showed several morphological alterations, compatible with the
hypothesis of an azadirachtin interference with the functionality of the microtubule organizing centres and with
the assembly of cytoskeletal microtubules, which are both fundamental processes in Plasmodium gametogenesis
and ookinete formation.
Conclusions: This work demonstrated in vivo transmission blocking activity of an azadirachtin-enriched neem seed
extract at an azadirachtin dose compatible with ‘druggability’ requisites. These results and evidence of anti-
plasmodial activity of neem products accumulated over the last years encourage to convey neem compounds into
the drug discovery & development pipeline and to evaluate their potential for the design of novel or improved
transmission-blocking remedies.
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In the last decade, a renewed commitment to the fight
against malaria has arisen from governments of endemic
countries and international organizations, with the expli-
cit aim to eliminate the disease in low transmission set-
t i n g sa n dt or e d u c ei t sb u r d e ni nh i g ht r a n s m i s s i o n
areas through high coverage application of insecticide
treated mosquito nets and artemisinin-based combina-
tion therapy (ACT) [1]. An important advantage of ACT
is that, when applied on a wide scale, it can impact on
transmission intensity of the disease, thanks to the
gametocytocidal activity of artemisinin derivatives [2].
Artemether in particular significantly reduces the den-
sity of the Plasmodium falciparum sexual stages that
persist in the circulation of patients treated with non-
gametocytocidal drugs for more than three weeks [3].
The long gametocyte life span of P. falciparum allows
the parasite to propagate to blood-seeking mosquitoes
for a prolonged period, thus increasing its chances to be
transmitted to other human hosts. Moreover, there is
evidence that the stress imposed to parasites by drug
treatment determines an up-regulation in the produc-
tion of sexual stages [4]. These observations imply that
treating patients with schizonticidal drugs has the
unwanted detrimental ‘side effect’, from a public health
perspective, of favouring the transmission of the para-
site, thus jeopardising malaria control efforts at commu-
nity level. Furthermore, this mechanism may enhance
the spread of drug resistance, once resistant parasite
clones have developed within a plasmodial population
[4]. Conversely, it has been demonstrated that the use of
ACT can counteract the spread of parasite strains
already resistant to one of the partner drugs [5].
A number of clinical studies conducted over the last
years to evaluate the curative efficacy of different formu-
lations of ACT have evidenced the transmission-blocking
potential of the treatments: artemisinin-, artemether- and
artesunate-based combinations, unlike other drugs/drug
combinations, such as chloroquine (CQ), quinine and
sulphadoxine-pyrimethamine [6-8], were found to
decrease the prevalence of gametocytaemia [9,10] and
mosquito infection [11,12]. However, membrane feeding
assays showed that around 60% and 40% of children trea-
ted with artemether-lumefantrine and sulphadoxine-pyri-
methamine plus artesunate, respectively, were still
infective to mosquitoes on day 14 after the beginning of
the treatment [13], indicating that gametocytaemia
reduction after ACT treatment is a slow process, requir-
ing 3-4 weeks [14-16]. This represents an obvious limita-
tion for the potential of ACT as a transmission-blocking
tool. Also, the first evidences of P. falciparum resistance
to artemisinin derivatives [17-19] are casting a shadow
over the future of malaria control with ACT.
The search for new transmission-blocking compounds
to back up the artemisinins’ gametocytocidal action and
to reduce the chances for the diffusion of resistant para-
sites is, therefore, of great importance. Such compounds
ideally should be directed against the mature forms of
gametocytes, and/or against the stages of the parasite
developing in the vector.
Medicinal plants represent a possible source for the
discovery of anti-plasmodial molecules. Extracts of the
neem tree (Azadirachta indica, Meliaceae) are used tra-
ditionally to treat malaria and other illnesses in several
endemic countries [20,21]. The efficacy of these extracts
is attributed to limonoids, a class of highly oxygenated
terpenoids [22], endowed with a range of biological
properties including insecticidal, anti-microbial, anti-
inflammatory and immuno-modulatory activities [23].
Several studies demonstrated that A. indica leaf, seed
and stem bark extracts possess in vitro inhibitory activ-
ity on P. falciparum asexual stages [24-29]. In vitro
screening of purified limonoids revealed that gedunin
and nimbolide are the most active molecules against
P. falciparum [24,30-32]. Gedunin was found to be
effective against CQ-resistant strains of the parasite,
with estimated IC50 of 0.72 and 1.25 in different studies
[32,33].
In vitro gametocytocidal activity of neem leaf and seed
extracts on P. falciparum has been reported [25,28]. In
a recent study, in particular, a neem leaf extract was
demonstrated to eliminate more than 90% of P. falci-
parum immature and mature gametocytes in culture, at
a concentration of 2.5 μg/ml [29]. Azadirachtin, a limo-
noid present in neem leaves, and particularly abundant
in neem seeds, was observed to inhibit in vitro P. falci-
parum and P. berghei microgamete exflagellation [34].
Cellular studies revealed that azadirachtin prevents the
microgametocyte from completing the three endomi-
toses required for microgametogenesis, and inhibits
cytoskeletal functions [35].
However, the in vivo inhibitory effect of azadirachtin
on male gametogenesis, and the effect of azadirachtin
and other limonoids on parasite stages developing in the
vector have not been explored yet. This work aims at
assessing the transmission blocking potential of NeemA-
zal® (a standardized, azadirachtin enriched extract of
neem seeds), using a rodent malaria model.
Methods
Experimental model
The rodent malaria model P. berghei/An. stephensi/
BALB/c mouse was used for the experiments. This
model has been validated as appropriate for obtaining
inferences on the potential of compounds as P. falci-
parum transmission-blocking agents [36]. The An.
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a photoperiod of 12 h. BALB/c mice, used as vertebrate
hosts, were reared in the animal facilities of the Depart-
ment of Experimental Medicine and Public Health of
the University of Camerino, Italy. Female mice weighing
16 - 19 g were used in the experiments. Blood meals
were carried out on mice anaesthetized with xylazine :
acepromazine 6.5 : 3.5, at a dosage of 11 mg/kg of the
mixture. Experimental animal rearing and handling were
fully compliant with the Italian Directive 116 of 10/27/
92 on the “use and protection of laboratory animals”,
and in adherence with the European regulation (86/609)
of 11/24/86 (licence no. 125/94A, issued by the Italian
Ministry of Health).
The P. berghei ANKA (CQ-sensitive) strain was main-
tained by weekly blood transfer from infected to healthy
mice. Every second month a cyclic passage was carried
out by infecting mosquitoes through a blood meal on
gametocytemic mice and, three weeks afterwards, by
transferring the parasite to healthy mice through the
bites of the sporozoite carrying mosquitoes. Mosquitoes
infected with P. berghei were kept at 19 ± 1°C for the
whole duration of the sporogonic cycle [37].
Neem products
The following neem products were used: i) NeemAzal®
technical grade (NA; Trifolio-M GmbH, Lahnau, Ger-
many), a standardized extract of A. indica seed kernels,
containing limonoids at a concentration of 57.6% [38] and
azadirachtin A at 34% (table 1); ii) azadirachtin tech grade
(AZA; Sigma). Stock solutions of the neem products were
prepared in absolute ethanol, at an azadirachtin A concen-
tration of 50 mg/ml, according to manufacturers’ informa-
tion about azadirachtin content in the extracts.
Experimental mice received intraperitoneal (ip) inocu-
lations of the various test solutions in a volume of 100
μl/mouse, obtained by dilution of the stock solutions
with PBS (pH 6.5) with the addition of Tween 80 and
DMSO, to final solvent concentrations of 5 - 20% etha-
nol, 7,5% Tween 80 and 10% DMSO. Control mice were
inoculated with solutions containing solvents only, with
20% ethanol, the maximum alcoholic concentration pre-
sent in the highest test dosage.
Evaluation of the impact on the sporogonic development
Experimental mice were infected by ip inoculation of
10
7 infected red blood cells and, four days after
infection, the presence of mature gametocytes was veri-
fied on Giemsa stained blood smears. Three gametocyte-
m i cm i c ew e r eu s e df o re a c ho ft h ef i v et r e a t m e n t s ,
namely NA 13.2 mg/kg, NA 25 mg/kg, NA 50 mg/kg,
AZA 50 mg/kg, and control solutions. Sixty minutes
after receiving the treatment, the mice were narcotized
and placed, according to the treatment, over cages con-
taining ~250 An. stephensi females, 5 - 7 day old. Nearly
all of the mosquitoes appeared successfully fed within
30 - 45 minutes. Unfed mosquitoes were discarded 24
hours after the blood meal. Ten days after the blood
meal, samples of about 40 mosquito females per treat-
ment group were dissected and their midguts examined
under the light microscope (400×) to assess oocyst pre-
sence and count their number. Log transformed oocyst
densities were compared using the Student’s t test.
Oocyst prevalences were compared using the c
2 test.
The experiment was replicated three times.
Assessment of mosquito infectivity
As another measure to assess sporogonic cycle blockage
by the neem treatments, healthy mice were challenged
by 10 - 15 bites each, using the treated mosquitoes,
three weeks after the infective blood meal. Two mice
were used per treatment group and Giemsa-stained thin
smears were observed to ascertain mouse positivity for
P. berghei one week after the challenge.
Evaluation of the impact on early sporogonic stages,
developing in the midgut lumen
To determine the effect of neem substances on gamete-
to-ookinete development mice were treated and exposed
to mosquitoes as described above and mosquitoes from
each treatment group were dissected to detect and
count ookinetes in the midgut lumen, 18 and 20 hours
after the blood meal, i.e. at a time when P. berghei
gametogenesis, fecundation and ookinete development
are completed. Midguts were excised in a drop of calf
serum, transferred to Eppendorf tubes in pools of three
and homogenized in 4 μl of calf serum. Three microli-
ters of the homogenate were smeared onto a glass slide
and stained with Giemsa. Ten to eleven slides (30-33
mosquitoes) were prepared for each treatment group.
Zygotes, immature (retort stage to elongated shape with
marginal nucleus) and mature ookinetes were counted
over 300 microscopic fields (1,000×) on each slide, fol-
lowing a cross-shaped transect. The experiment was
repeated twice. Log transformed midgut stages’ densities
were compared using the Student’s t test.
To verify whether NA treatment altered the zygote
and/or ookinete morphology and whether it inhibited
the formation of mature ookinetes, 9 out of 21 slides
from the two NA 50 mg/kg treatment replicates were
extensively screened over a total area of 628 mm
2 (15%
Table 1 Limonoid content of NeemAzal®
azadirachtin A 34%
other azadirachtins (azadirachtin B to K) 16%
salannins 4%
nimbins 2%
Total limonoids 56%
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were found and inspected.
Evaluation of the impact on oocyst maturation
To establish if neem substances interfere with the
maturation of oocysts, infected (untreated) mosquitoes
were offered a second blood meal on neem-treated
mice. About 1,800 An. stephensi females were infected
with P. berghei through a blood meal on gametocytae-
mic mice. On day 7 after the infective blood meal, the
mosquitoes were offered a second blood meal, according
to the procedure described above, on three groups of
three uninfected mice treated with 50 mg/kg NA,
50 mg/kg AZA, or control solutions. On day 10 after
the first, infective blood meal (day 3 after the second
blood meal), samples of mosquitoes from the three
experimental groups were dissected, and oocyst num-
bers and their stage of development were recorded. The
oocyst developmental status was coded into three cate-
gories, namely: s1, immatureo o c y s t ,b e f o r et h ef o r m a -
tion of sporoblasts (Figure 1A); s2, immature oocyst,
with visible sporoblasts and budding sporozoites (Figure
1B1 and 1B2); s3, mature oocyst containing fully devel-
oped sporozoites (Figure 1C). Log transformed oocyst
densities were compared using the Student’s t test.
Results
Block of the sporogonic development
The development of P. berghei in An. stephensi mosqui-
toes was blocked when the sexual stages of the parasite
were ingested by females taking a blood meal on NA-
treated, gametocytaemic mice. Within the NA 50 mg/kg
treatment group, none of the 138 mosquitoes examined
in three consecutive experiments revealed the presence
of oocysts (Table 2).
This blockage of the sporogonic development was
confirmed by mouse challenge: all the healthy mice
(n = 6) exposed to 10 - 15 bites of mosquitoes fed on the
NA 50 mg/kg treated gametocytaemic mice failed to
develop Plasmodium infections, whereas all the mice
(n = 6) exposed to control mosquitoes had positive blood
slides on day 7 after the challenge.
No impact on the sporogonic development could be
detected in mosquitoes of the other neem treatment
groups, namely NA 25 mg/kg, NA 13.2 mg/kg and AZA
50 mg/kg (Table 2). In these groups, the percentage of
oocyst-positive mosquitoes was high in all occasions,
most often above 80%, and very similar in treatment
and control mosquitoes. Also, NA at these dosages and
A Z Ad i dn o ta p p e a rt ob ea b l et or e d u c et h en u m b e ro f
oocysts and all the mice challenged with mosquitoes
from these treatment groups developed parasitaemia.
Impact on early sporogonic stages, developing in the
midgut lumen
Mean early midgut stage (zygotes + ookinetes) densities
were severely affected by NA action, as evidenced by
mosquito midgut smears prepared 18 and 20 hours after
the infective blood meal (Figure 2). Mean zygotes +
ookinetes densities, estimated through counts on 300
microscopic fields (mf), amounted in the control mos-
quitoes 15.7 (CI95 6.1 - 38.4) and 10.6 (CI95 6.2 - 18.2)
in the 1
st and 2
nd experiment, respectively, compared to
only 2.1 (CI95 1.0 - 3.9) and 2.9 CI95 1.5 - 5.1) in mos-
quitoes fed on 50 mg/kg NA treated mice. These results
show that NA at 50 mg/kg significantly reduced
the number of parasites able to reach the zygote stage
(p = 0.001 and p = 0.002 for the 1
st and 2
nd experiment,
respectively).
The mean zygotes + ookinetes densities of mosquitoes
fed on NA 25 mg/kg and AZA 50 mg/kg treated mice
were lower than those of the controls, ranging from 4.6
to 6.7 (NA 25 mg/kg 1
st e x p . :6 . 1 ,C I 95 2.6 - 12.9; 2
nd
exp.: 6.7, CI95 3.7 - 11.7; AZA 50 mg/kg 1
st exp.: 4.6,
CI95 1.8 - 10.3; 2
nd exp.: 6.3, CI95 4.2 - 9.2), but the dif-
ference was not statistically significant.
Figure 1 Light microscope images (400×) of Plasmodium berghei oocyst development stages (day 10 after mosquito infection).
Immature oocyst, with uniform content, A; immature oocysts, with sporoblasts and budding sporozoites, B1 and B2; mature oocyst, with fully
developed sporozoites visible, C.
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Page 4 of 10Table 2 Effect of NeemAzal® on P. berghei oocyst prevalence and density on mosquito midguts
Treatment* Experiment
† % Prevalence (CI95) Oocysts/mosquito (CI95)
# Examined mosquitoes
control 1 90 (81 - 99) 17.5 (11.1 - 27.2) 40
2 83 (68 - 99) 29.9 (15.8 - 55.8) 24
3 100 111.2 (83.8 - 148.9) 40
4 86 (72 - 100) 35.2 (21.6 - 57.6) 22
5 88 (78 - 98) 11.3 (7.2 - 17.4) 42
6 89 (80 - 97) 26.1 (15.8 - 42.4) 53
tot
‡ 90 (86 - 94) 27.7 (22.3 - 34.2) 221
NA 13.2 mg/kg 4 82 (64 - 100) 49.9 (24.5 - 100.5) 17
5 79 (66 - 91) 12.7 (8.6 - 18.7) 42
6 100 39.4 (30.5 - 50.9) 58
tot 90 (84 - 95) 28.9 (23.0 - 36.3) 117
NA 25 mg/kg 3 90 (81 - 99) 42.8 (26.7 - 69.1) 40
5 69 (55 - 84) 8.9 (5.4 - 14.2) 39
6 96 (91 - 100) 30.5 (22.3 - 41.1) 54
tot 86 (81 - 92) 25.6 (19.9 - 32.8) 133
NA 50 mg/kg 1 0 0 55
20 0 4 3
30 0 4 0
tot 0 0 138
AZA 50 mg/kg 3 95 (88 - 100) 23.3 (15.0 - 36.0) 41
5 88 (78 - 98) 24.3 (17.2 - 34.5) 42
6 83 (68 - 99) 3.2 (2.0 - 5.0) 24
tot 90 (73 - 100) 16.1 (12.2 - 21.2) 107
Oocyst prevalence and intensity was assessed on day 10 after the infective blood meal carried out on mice treated with the indicated products and doses.
* NA = NeemAzal® technical grade (Trifolio-M GmbH); AZA = azadirachtin tech grade (Sigma).
† each number corresponds to one experimentation involving
different treatment groups.
# geometric means, only positive mosquitoes included.
‡ values refer to pooled data.
Figure 2 Effects of the neem products on P. berghei midgut stages (zygotes to ookinetes). Parasites were counted on 300 microscopic
fields (1000× magnification) of midgut content smears of A. stephensi females that had fed 18 (A), and 20 (B) hours before on mice treated with
the indicated neem products and doses. NA25, NeemAzal® 25 mg/kg; NA50, NeemAzal® 50 mg/kg; AZA50, azadirachtin 50 mg/kg. Geometric
means of zygote + ookinete densities, evaluated over ten smears (30 mosquitoes), with 95% confidence intervals (green bars; left axis). Mature
ookinetes/total midgut forms ratio (orange bars; right axis). * means differ significantly from control (Student’s t test; p ≤ 0.002).
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after the infective blood meal, no mature ookinetes were
detected on the midgut slides of NA 50 mg/kg treated
mosquitoes (Figure 2), suggesting that the treatment
interferes with the process of ookinete development.
Accordingly, the additional extensive screening of 9
slides from this group, covering 15% of the total smear
area, revealed the presence of 90 zygotes and post-zygo-
tic forms, with no mature ookinete. For comparison, in
control mosquitoes, 1/3 to 5/6 of the midgut stages pre-
sent 18 or 20 hours after the infective blood meal were
mature ookinetes (Figure 2).
The morphological comparison of the zygotes and
post-zygotic forms traced on NA 50 mg/kg slides with
controls allowed alterations of the post-zygotic stages to
be detected (Figure 3), whereas zygotes did not appear
to differ. Giemsa-stained zygotes from both groups were
similar in size, displaying rounded, condensed nuclei,
intense cytoplasmic coloration and comparable haemo-
zoin granules and crystalloid precursors (Figure 3A, 3I
to 3J). In the control group, the ookinete development
from retort stages (Figure 3B to 3F) to mature ookinetes
(Figure 3G, 3H) was characterized by the completion of
the elongation process, with the disappearance of the
residual bulbous end containing the condensed nucleus,
an intense staining of the apical region and the appear-
ance of well defined haemozoin-surrounded crystalloid
organelles. Several morphological alterations of the post-
zygotic forms were found in the NA 50 mg/kg group
(Figure 3K to 3T):
i) irregular cell shape (Figure 3L, 3M) and jagged cell
borders (Figure 3K, 3N, 3O, 3R to 3T);
ii) lack of intense nuclear staining, with the nuclear
material appearing dispersed within the cytoplasm
(Figure 3O to 3T);
iii) weak staining, if any, of the apical region (Figure
3L, 3O to 3Q, 3S, 3T);
iv) lack of crystalloid assembly, the organelle granules
remaining dispersed as in the zygote stage (Figure 3K,
3M to 3S), or partial crystalloid assembly (Figure 3L,
3T).
Evaluation of impact on oocyst maturation
The exposure of early P. berghei oocysts to NA and
AZA through a second treated blood meal on day 7
after mosquito infection did not affect the oocysts’ sub-
sequent development. In both neem treated groups
oocysts underwent regular sporoblast formation and
sporozoite maturation, as in untreated mosquitoes. Also,
the proportion of mature oocysts containing fully devel-
oped sporozoites (stage s3) was similar in treated and
control groups. Salivary glands were successfully invaded
by sporozoites in both groups, indicating that neem
treatment was not able to interfere with the sporogonic
cycle (Table 3).
Discussion
NeemAzal® (NA), a commercial A. indica seed extract,
containing the limonoid azadirachtin as the main com-
ponent, completely blocked the development of P. ber-
ghei in An. stephensi mosquitoes fed on gametocytaemic
mice treated with the extract at 50 mg/kg body weight.
The treated mosquitoes did not produce oocysts and
were thus unable to infect healthy mice. The examina-
tion of slides prepared from the midgut content of
experimental mosquitoes showed that NA activity was
directed to the early sporogonic stages: the total number
of zygotes and post-zygotic forms was reduced in the
NA-treated group compared to controls, indicating that
NA components interfere with parasite development
already before zygote formation. In addition, post-zygo-
tic forms from NA treated mosquitoes displayed evident
morphological alterations and no mature ookinetes
could be detected. These results indicate that NA may
act on gametogenesis and ookinete formation.
In vitro studies conducted by Jones and colleagues
[34] showed that azadirachtin interferes with the exfla-
gellation process of P. falciparum and P. berghei micro-
gametocytes, inducing an interruption of the
endomitotic divisions and the formation of rigid exten-
sions on axonemes, preventing their motility [34]. In a
subsequent study it was demonstrated by Billker et al
[35] that azadirachtin disrupts cytoplasmic and axone-
mal microtubule organization, possibly by compromising
the functionality of the microtubule organizing centres
(MTOC), including spindle plaques. The results pre-
sented in this report suggest that azadirachtin inhibits
microgametogenesis in vivo.
The morphological alterations observed on NA-treated
post-zygotic forms are compatible with the hypothesis
that azadirachtin interferes with ookinete formation via
a possibly similar, microtubule-targeted mechanism of
action. The irregular cell shape, the jagged cell mem-
brane, the inability to form the typically strongly stained
apical complex and to perform the elongation process
are compatible with an interference with the microtu-
bule organizing processes involved in cytoskeletal and
organelle rearrangements. Electron microscopy studies
have shown that ookinete development is depending on
the differentiation of a MTOC at the apical pole, from
which subpellicular, longitudinal microtubules radiate
and the triple membrane (pellicle) is formed [39,40].
Further evidence for azadirachtin action on microtubule
organizing processes is available from studies of Salehza-
deh and colleagues [41], who showed that the antimito-
tic activity of azadirachtin observed on cultured insect
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Page 6 of 10Figure 3 Light microscope images (1000×) Giemsa stained P. berghei zygotes and ookinetes from A. stephensi midgut content smears,
18 - 20 hours after the infective blood meal. Control mosquitoes, A to H; NeemAzal® 50 mg/kg treated mosquitoes, I to T. See text for
details.
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merization, through a mode of action resembling that of
colchicine. Colchicine and other compounds of natural
origin, added to zygote cultures of Plasmodium gallina-
ceum, have been demonstrated to inhibit ookinete for-
mation [42].
The fact that a transmission blocking action was
observed with NA, but not with AZA tested at the same
dose, might suggest that other bioactive limonoids pre-
sent in the former (which is an azadirachtin-enriched
extract, not a pure azadirachtin molecule) could explain
t h ed i f f e r e n c ei na c t i v i t y .H o w e v e r ,aH P L Ca n a l y s i s
conducted according to the protocol of Kaushik [43] did
not evidence additional compounds present in signifi-
cant amounts in NA, but revealed that the azadirachtin
A content of AZA was about half the amount declared
by the manufacturer, which could well explain the dif-
ference in transmission blocking effect observed with
the two products.
Numerous studies demonstrated that azadirachtin and
other limonoids present in neem extracts are active on
insects [44], including malaria vectors [45-47]. Exploring
the insecticidal properties of NA in An. stephensi, it was
found that mosquitoes fed with artificial blood meals or
sugar solutions containing a NA concentration corre-
sponding to 100 μg/ml azadirachtin displayed reduced
blood feeding capability and produced fewer eggs. This
reduction in oviposition was mirrored by a degenerative
tissue damage provoked by NA on ovarian follicles [48].
These multiple and diverse effects on Plasmodium
midgut stages and female mosquitoes are of remarkable
interest in view of the development of transmission
blocking molecular tools, directed against both the
malaria parasite and the malaria vector, based on neem
extracts. To challenge their potential, the identification
of the bioactive molecules and the characterization with
respect to target stage and mode of action represent
important research questions to be addressed. Also, the
‘druggability’ of limonoids may represent a major chal-
lenge: the few studies that explored limonoid
pharmacokinetics indicate a relatively short half-life and
low bioavailability of the compounds. Manners et al [49]
report that limonin and related metabolites were not
detectable in plasma samples of human volunteers 24
hours after the administration of 30 mg/kg of pure
limonin glucoside, which reached its peak plasma con-
centration 6 hours post-administration. Lack of in vivo
curative activity of gedunin against P. berghei has been
ascribed to its poor absorption in the digestive tract
[20].
Developing transmission blocking drug candidates
from neem compounds is a long and challenging way to
go. Still, evidences accumulated over the years on the
anti-plasmodial and mosquito-toxic activity of plants
encourage medicinal chemistry studies aiming to
develop limonoid leads with improved bioavailability
characteristics. Once limonoid leads are obtained, drug
interaction studies with ACT would be required and
possible interactions with the immune system should be
assessed, before considering them for further develop-
ment as transmission-blocking components of combina-
tion therapies.
As an equally challenging alternative, the development
of neem-based transmission blocking remedies by
improving traditional herbal treatments could be
explored. Extract fractions displaying a high activity
against gametocytes and/or against the Plasmodium
stages developing in the vector can be identified apply-
ing bio-guided fractionation methods. Combining the
most active fractions should result in remedies with an
increased overall transmission blocking efficacy, thanks
to potentially additive or synergistic effects of azadirach-
tin, other limonoids and other components present in
extracts [50]. In addition the presence of various bioac-
tive molecules in the extracts might reduce the likeli-
hood of selecting resistant strains in the target
organisms [45]. On the other hand, toxicity and variabil-
ity of preparations must be taken into account when
considering plant extracts for therapeutic use, as the
useful metabolites’ concentration may vary widely
Table 3 P. berghei oocyst number/mosquito and development stage proportions after a secondary, treated blood
meal
Treatment Replication Stage of development* Total (CI95%) Examined mosquitoes
s1 (%) s2 (%) s3 (%)
control 1 25 (38) 23 (37) 12 (25) 70 (50 - 98) 27
2 15 (33) 12 (31) 13 (36) 54 (42 - 70) 92
NA 50 mg/kg 1 10 (36) 10 (36) 8 (28) 31 (19 - 49) 23
2 30 (42) 21 (33) 11 (25) 82 (68 - 100) 112
AZA 50 mg/kg 1 19 (34) 20 (35) 18 (31) 61 (40 - 93) 27
Secondary blood meals were carried out on mice treated with the indicated products and doses on day 7 after mosquito infection. Oocysts were evaluated on
day 3 after the secondary blood meal (day 10 post infection). *s1: immature oocysts, before the formation of sporoblasts (fig. 1A); s2: immature oocysts, with
visible sporoblasts and budding sporozoites (fig. 1 B1 - B2); s3: mature oocysts containing fully developed sporozoites (fig. 1C). Geometric means, only positive
mosquitoes included.
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gin, mode of plant collection and storage [51]. In the
case of neem preparations, not only toxicity risks, but
possible immuno-modulatory effects also need to be
explored before considering a product for human use
[52].
Conclusion
The neem tree, A. indica, produces and stores in its
organs and tissues secondary metabolites that have been
demonstrated to be active against different malaria para-
site stages in the vertebrate host and to possess insecti-
cidal and insect growth regulatory properties on malaria
vectors as well. The transmission blocking activity of a
standardized, azadirachtin rich neem extract described
in this work represents an additional element contribut-
ing to the potential of neem as a resource for malaria
control. The available eviden c es t r o n g l ye n c o u r a g e st o
convey neem compounds in the drug discovery and
development pipeline and also to evaluate the potential
of plant extracts for the development of improved tradi-
tional remedies.
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